EMERYVILLE, Calif., Jan 15 /PRNewswire-FirstCall/ -- Bionovo, Inc. will participate in the CBI Menopause Pharmacotherapeutic Development Conference taking place Jan. 18-19 at the Hilton Philadelphia City Avenue in Philadelphia. Dr. Isaac Cohen, President and CEO, Bionovo and Dr. Mary Tagliaferri, Chief Medical Officer, Bionovo will present details about the development of MF101, the company’s lead candidate currently being evaluated in Phase 2 trials as a safer, effective alternative to traditional hormone therapy.
The presentation, titled “MF101 -- An Estrogen Beta Receptor Agonist for Menopausal Hot Flashes: Mechanism of Action and Selectivity,” is scheduled for 9:00 a.m. EST on Friday, Jan. 19.
To access a live audio webcast or the subsequent archived recording, log on to www.bionovo.com . Please connect to Bionovo’s website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary. For additional information on the conference, visit: www.cbinet.com/menopause .
About Bionovo, Inc.
Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women’s health. The company has two drugs in clinical testing. MF101 is in Phase 2 for quality of life conditions associated with menopause and BZL101 is in Phase 1/2 for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in development for breast cancer, pancreatic cancer and other menopausal symptoms with a total of 5 drug candidates expected to be in clinical trials by the end of 2007. The company is developing its products in close collaboration with leading U.S. academic research centers, including the University of California, San Francisco, University of Colorado Health Sciences Center, University of California, Berkeley, and the University of Texas Southwestern Medical Center in Dallas, TX. For further information please visit: http://www.bionovo.com .
Bionovo, Inc.
CONTACT: Jim Stapleton, Chief Financial Officer, of Bionovo, Inc.,+1-510-601-2000, or jim@bionovo.com; or investors, Antima “Taz” Sadhukhan,of Investor Relations Group, +1-212-825-3210, for Bionovo, Inc.
